Bionano Genomics, Inc. (BNGO) |
|
2.89 -0.36 (-11.08%)
|
08-19 01:49 |
|
Open: |
3.23 |
Pre. Close: |
3.25 |
|
High:
|
3.29 |
Low:
|
2.835 |
|
Volume:
|
12,089,191 |
Market Cap:
|
839(M) |
|
|
|
|
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.46 - 3.48 |
3.48 - 3.49 |
|
Low:
|
3.12 - 3.15 |
3.15 - 3.17 |
|
Close:
|
3.22 - 3.25 |
3.25 - 3.28 |
|
Technical analysis |
as of: 2022-08-18 3:51:14 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 3.79  One year: 5.08 |
| Support: |
Support1: 1.46 Support2: 1.21 |
| Resistance: |
Resistance1: 3.24 Resistance2: 4.34 |
| Pivot: |
2.71  |
| Moving Average: |
MA(5): 3.33 MA(20): 2.48
MA(100): 1.85 MA(250): 2.98 |
| MACD: |
MACD(12,26): 0.4 Signal(9): 0.3 |
| Stochastic oscillator: |
%K(14,3): 53.8 %D(3): 62.3 |
| RSI: |
RSI(14): 58 |
| 52-week: |
High: 6.28 Low: 1.15 |
| Average Vol(K): |
3-Month: 8,463 (K) 10-Days: 20,258 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BNGO ] has closed below upper band by 44.5%. Bollinger Bands are 226.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue. |
|
|
Headline News |
Thu, 18 Aug 2022
BioNano Genomics Inc (BNGO) is lower by 1.85% Thursday In Premarket Trading - InvestorsObserver
Thu, 11 Aug 2022
Why Is Bionano Genomics (BNGO) Stock Up 20% Today? - InvestorPlace
Wed, 03 Aug 2022
BNGO, NTLA and OPTT are among pre market gainers - Seeking Alpha
Tue, 02 Aug 2022
BioNano Genomics (BNGO) Stock: Why It Increased Over 9% Today - Pulse 2.0
Mon, 01 Aug 2022
Bionano Genomics Announces Publication of Landmark Research Study in Myelodysplastic Syndrome Showing OGM Data would Result in Revised Prognostic Risk Classification or Additional Actionable Variants in 28% of Study Participants - Yahoo Finance
Thu, 28 Jul 2022
2022-07-28 | NDAQ:BNGO | Press Release | Bionano Genomics Inc. - Stockhouse
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
290 (M) |
| Shares Float |
284 (M) |
|
% Held by Insiders
|
1.9 (%) |
|
% Held by Institutions
|
25.9 (%) |
|
Shares Short
|
44,170 (K) |
|
Shares Short P.Month
|
38,050 (K) |
Stock Financials |
|
EPS
|
-0.33 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.98 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-471.6 |
|
Return on Assets (ttm)
|
-20.3 |
|
Return on Equity (ttm)
|
-33.6 |
|
Qtrly Rev. Growth
|
73 |
|
Gross Profit (p.s.)
|
0.01 |
|
Sales Per Share
|
0.08 |
|
EBITDA (p.s.)
|
-0.36 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-106 (M) |
|
Levered Free Cash Flow
|
-59 (M) |
Stock Valuations |
|
PE Ratio
|
-8.68 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.9 |
|
Price to Sales
|
35.34 |
|
Price to Cash Flow
|
-7.75 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
